Diagnosis and Treatment of Angiography Positive Medium to Large Vessel Childhood Primary Angiitis of Central Nervous System (p-cPACNS): An International Survey

Angela S. Quan¹, Jürgen Brunner², Benjamin Rose¹, Martin Smitka³, Gabriele Hahn⁴, Clare E. Pain⁵, Renate Hähner⁶, Fabian Speth⁷, Lucia Gerstl⁸ and Christian M. Hedrich¹,⁵*

¹Department of Women's and Children’s Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom, ²Pädiatrische Rheumatologie, Department Kinder- und Jugendheilkunde, Klinisches Ethikkomitee, Medizinische Universität Innsbruck, Innsbruck, Austria, ³Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ⁴Institut und Poliklinik für Radiologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ⁵Department of Paediatric Rheumatology, Alder Hey Children’s NHS Foundation Trust Hospital, Liverpool, United Kingdom, ⁶Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen, Germany, ⁷Zentrum für Geburtshilfe, Kinder- und Jugendmedizin, Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Eppendorf, Hamburg, Germany, ⁸Division of Paediatric Neurology, Developmental Medicine and Social Paediatrics, Department of Paediatrics, Dr. von Hauner Children’s Hospital, Ludwig-Maximilians-University Munich, Munich, Germany

Childhood Primary Angiitis of Central Nervous System (cPACNS) is rare, but can cause significant damage and result in disability or even death. Because of its rarity, the sometimes acute and variable presentation, limited awareness, and the absence of widely accepted diagnostic and therapeutic standards, cPACNS is a diagnostic and therapeutic challenge. Three subcategories of cPACNS exist, including angiography-positive non-progressive p-cPACNS, angiography-positive progressive p-cPACNS which both affects the medium to large vessels, and angiography-negative small vessel sv-cPACNS. Diagnosis and treatment of cPACNS relies on personal experience, expert opinion and case reports/case series. To collect information on diagnostic and therapeutic approaches to transient and progressive cPACNS, a survey was shared among international clinicians (German Society for Pediatric Rheumatology, the Pediatric Rheumatology European Society, the German speaking “Network Pediatric Stroke,” and members of the American College of Rheumatology/CARRA Pediatric Rheumatology list server). Results from this survey will be used to define statements toward a consensus process allowing harmonization of diagnostic and therapeutic approaches and the generation of evidence in a rare condition.

Keywords: vasculitis, CNS, childhood, pediatric, treatment, diagnosis, inflammation, CNS inflammation
To optimize and harmonize diagnostic and therapeutic approaches consensus treatment plans (CTP) can be a tool in rare conditions where clinical trials are currently not available or realistic, such as p-cPACNS. They allow prospective data collection on therapy and associated outcomes. As a first step, real-life standard of care requires to be documented to develop statements e.g., through Delphi surveys that can then be used toward an expert consensus conference for CTP development (11, 12).

We describe a survey undertaken with international experts in which we sought information on diagnostic and therapeutic strategies in transient and progressive p-cPACNS.

METHODS

Instrument

A survey was designed to collect information on diagnostic and therapeutic approaches in p-cPACNS by experts in the field. It consisted of introductory questions addressing demographics (sub-specialty, country of practice) and experience of participants, and 2 case scenarios accompanied by multiple choice questions. One case (case 1) represented a patient with progressive p-cPACNS, the second (case 2) had two alternative outcomes: transient p-cPACNS likely not related to VZV, and transient p-cPACNS likely related to VZV. Survey details can be accessed in Supplementary Material 1. Case based questions aimed at determining examinations deemed important to diagnose p-cPACNS. The survey also queried how participants would treat and follow patients with transient or progressive p-cPACNS. Lastly, respondents were asked which specialties they consider important to be involved in the diagnosis and treatment of p-cPACNS patients. Multiple choice answers were provided, as well as the option to add comments and/or additional answers (Supplementary Material 1).

The survey was conducted online using the web-based tool Survey Monkey (Survey Monkey Inc.; California, USA; www.surveymonkey.com). A link to the survey was sent to addressees in August 2019 and the survey was open for 2 months. A reminder e-mails was sent out at both 4 and 6 weeks after the initial survey link was shared. The survey was distributed among colleagues from Europe, North America, and globally with experience in the diagnosis and treatment of p-cPACNS. This was achieved through member email lists of the German Society for Pediatric Rheumatology (GKJR) (n = 151; Pediatric Rheumatologists; personal email), the Pediatric Rheumatology European Society (PRES) (n = 7,800; society members; monthly PRES email newsletter), members of the German speaking “Network Pediatric Stroke” with members in Germany, Austria and Switzerland (n = 72; including Pediatric Rheumatologists, Immunologists, Neurologists and specialists for pediatric haemostaseology; personal email), and subscribers to the American College of Rheumatology/CARRA Pediatric Rheumatology Bulletin Board (ped-rhe-list-bounces@mcmaster.ca) (n = 1849; personal email).

| TABLE 1 | Criteria for p-cPACNS. |
|----------|------------------------|
| **Pediatric criteria for p-PACNS (7–9)** | |
| Newly acquired neurological deficit | |
| Angiographic and/or histological features of angiitis within the CNS | |
| No evidence of an underlying systemic disorder that explains the symptoms | |
| Recently developed psychiatric deficits | |
Analysis of Response
Descriptive analysis of responses was performed using Microsoft Excel (Redmond, Washington, USA).

RESULTS
Responses, Demographics and Experience of Participants
The survey was answered by a total of 92 clinicians, with the majority of colleagues specializing in Pediatric Rheumatology (72, 78.2%), followed by 11 Pediatric Neurologists (11.9%), 4 General Pediatricians (4.3%), one Adult Rheumatologist, Pediatric Intensive Care Clinician, Pediatric Hematologist and Adult Neurologist each (Q1). The number of responses varied slightly between individual questions; the number of responses to each question are indicated throughout this manuscript. Experience of responders in their subspecialty varied, as did number of cases of cPACNS treated (Figures 1A,B, Q2, N = 92 responses). Figure 1C shows the distribution of where responders practiced (Q3, N = 85 responses).

Diagnostic Approach
To understand how participants approach the diagnosis of p-cPACNS, they were asked to rank 7 clinical, laboratory and imaging examinations weighing their importance for the diagnosis of pPACNS (Q5, N = 86 responses, Figure 2A). Median importance ranks (1–7) assigned to individual examinations were calculated, where 1 indicated the most important (Figure 2B). MRI imaging was most commonly ranked as the most important examination (median: 1), followed by CSF analysis (median: 3), inflammation parameters in blood, immunology in the blood (ANA, ENA, ds-DNA, ANCA, antiphospholipid antibodies, rheumatoid factor, complement system components and activation) (median: 4 both), conventional angiography, CSF immunology (encephalitis-associated antibodies) (median: 5 both) and lastly cranial CT (median: 6).

When asked whether genetic testing should be considered, 50/87 respondents (57.5%) felt that genetic testing should
indeed be performed (Q6, N = 87 responses), and among
34 respondents who specified, most suggested testing for
deficiency of adenosine deaminase 2 (DADA2; 21/34; 61.8%).
Further conditions mentioned included Ehlers-Danlos and
Marfan syndromes (2.9% each), systemic and organ-specific
inflammatory disorders, such as granulomatosis (familial),
hemophagocytic lymphohistiocytosis (HLH), Systemic lupus
erythematous (SLE), Sjögren’s syndrome, collagen tissue disease,
and Moya Moya disease.

Case Studies
After aforementioned general questions, the survey presented
two clinical scenarios addressing specific diagnostic and
therapeutic approaches.

Case 1
An 8-year-old boy presents with increasing fatigue (past 2
weeks) and new acute-onset symptoms of aphasia, ataxia,
headaches, and progressive vertigo for the past 24 h. He has
no personal or family history of clotting disorders, strokes or
autoimmune/inflammatory disease. He has had no infections in
the past year and no travel history (other than a “sore throat or
sniffles here and there”), no pets, and no other symptoms.

When asked about diagnostic approaches to this specific
case (Q7, N = 74 responses), respondents ranked emergency
MRI of the brain including angio-MRI (90.5%) and blood
tests including full blood counts, inflammatory markers and
clotting tests (90.5%) as most important. These were followed
by lumbar puncture to analyze the CSF (82.4%), and brain CT
scan including CT angiography (23.0%). Of the respondents
who considered blood tests essential (Q8, N = 74 responses),
98.6% would order full blood count including complete white
cell count, 97.3% would order clotting tests including PTT,
INR, fibrinogen and D dimers, and 94.6% would order
immunology tests including ANA, ENA, complement factors,
cardiopin antibodies and ANCA. When asked which blood
immunology tests they would order, 97.3% answered anti-
phospholipid antibody testing, followed by antinuclear antibody
testing (93.2%), requested anti-neutrophil cytoplasmic antibodies
(89.2%), anti-dsDNA antibodies (87.8%), complement factors
and activation of the complement cascade (83.8%), and
anti-NMDA (N-methyl-D-aspartate) receptor and aquaporin
antibodies (67.6%) (Q9, N = 74 responses). Of 74 respondents
who considered performing a lumbar puncture (Q10, N = 74 responses),
most (98.6%) would request cell counts,
differentiation and protein quantification, followed by microbial
culture (93.2%), glucose levels (90.5%), oligoclonal bands
(89.1%), CSF opening pressure (86.5%), lactate (74.3%) and
anti-NMDA and aquaporin antibodies (68.9%). When asked
about helpful MRI techniques (Q11, N = 71 responses), 87.3%
of responders requested MRI angiography, followed by fluid-
attenuated inversion recovery (FLAIR; 55/71; 77.5%), diffusion-
weighted MRI sequences (53/71, 74.7%), T1 with fat saturation
(FS; 30/71; 42.3%), T1FS with contrast medium (38/71, 53.5%),
T2FS (37/71, 52.1%), Turbo inversion recovery magnitude
(TIRM)/Short tau inversion recovery (STIR; 28/71; 39.4%).
Detailed results are summarized in Table 2.

Next, respondents were informed that the patient exhibited
elevated ESR (30mm/h) and CRP (4mg/L). Approximately
30 h after the onset of ataxia and aphasia, Magnetic Resonance
Imaging (MRI) shows alterations in proton diffusion capacity
in the Cerebellum and a significant and long ranging
stenosis of the distal Basilar artery in MRI angiography
(Supplementary Material 1).
Based on new information provided, respondents were asked to select 5 most likely differential diagnoses (Q12, \(N = 73\) responses). Most respondents selected progressive p-cPACNS (80.8%), followed by transient p-cPACNS (69.9%), ischaemic stroke (64.4%), congenital anatomical deformity (39.7%) and infections (38.4%). Asking indicators of likely progressive p-cPACNS (Q13, \(N = 73\) responses), the majority of respondents suggested imaging results (87.7%), followed by clinical course with disease progression over 3 months or more (69.9%), laboratory findings suggesting systemic inflammation (46.6%), acute presentation with “systemic signs” (43.8%), and response to immune modulation (41.1%). Detailed results are summarized in Table 3.

Next, the following information was provided: Autoantibodies in CSF and blood came back negative, there’s no evidence for clotting disorders or infection, including TB. Systemic inflammatory parameters remain normal. Based on the involvement of posterior arteries, the diagnosis of (likely) progressive p-cPACNS (Childhood Primary Angiitis of Central Nervous System) is made.

Participants were asked to decide which medication they consider for the induction of remission (Q14, \(N = 73\) responses). Sixty-eight of 73 respondents would start treatment with intravenous Methylprednisolone (IVMP) over 5 days, followed by oral prednisolone (93.2%), 47/73 (64.3%) consider treatment with intravenous Cyclophosphamide every month...
for 4–6 months, 9/73 (12.3%) would start treatment with mycophenolate mofetil (MMF), and 3/73 (4.1%) would treat with oral prednisolone. None of the respondents chose oral cyclophosphamide or azathioprine for induction treatment.

Considering prophylaxis of thromboembolic events (Q15, N = 70 responses), most responders agreed on administering IV heparin initially (65.7%), followed by acetyl salicylic acid (ASA), and a combination of ASA and clopidogrel. Considering post-acute phase thrombosis prophylaxis (Q16, N = 70 responses), the majority of respondents would prescribe aspirin (47.1%), followed by subcutaneous heparin (22.9%), a combination of ASA and clopidogrel (14.3%), warfarin (11.4%), clopidogrel alone (5.7%), or DOACs (2.9%). Opinions on when to discontinue anticoagulation treatments (Q20, N = 70 responses) were divided and ranged between 3 and 36 months. One respondent would not administer anticoagulation treatment (1.4%) (Table 4).

Considering immune modulating maintenance treatment (Q17, N = 73 responses), the majority of respondents (72.6%) would prescribe MMF, followed by azathioprine (20.5%), oral prednisolone (17.8%), intravenous cyclophosphamide (13.7%), rituximab (9.6%), methotrexate (5.5%), oral cyclophosphamide (following Fauci scheme) or TNF inhibitors (1.4% each). Opinions on the required duration of treatment were divided (Q18, N = 73 responses) and ranged between 3 and 36 months. When asked how long to include oral corticosteroid treatment in the regimen, including slow taper (Q19, N = 72 responses), respondents responded: 3 months (20.8%), 6 months (41.7%), 12 months (15.3%), 18 months (4.2%), 24 months (5.6%), 36 months (1.4%), and 1.4% indicated no corticosteroid treatment (Table 4).

Monitoring disease activity and damage using MRI (Q21, N = 72 responses), 56/72 (77.8%) respondents suggested to repeat MRI after 3 months, 36/72 after 6 months (50.0%), 25/72 after 12 months (34.7%), 11/72 after 18 months (15.3%), 21/72 after 24 months (29.1%), and 10/72 after 36 months (13.9%) and 11/72 answered other (15.3%). When asked when to schedule clinical follow up (Q22, N = 73 responses), 59/73 respondents indicated within 3 months (80.8%), 23/73 after 6 months (31.5%), 22/73 after 12 months (30.1%), 19/73 after 18 months (26.0%), 21/73 after 24 months (28.8%) and 15/73 after 36 months (20.6%).

Case 2
A 4-year-old girl presents with headaches and symptoms suggestive of a cerebrovascular stroke (vomiting with some language and speech delays). She has a past medical history of a clinically diagnosed Varicella Zoster Virus (VZV) infection 6 months ago. There’s no history of strokes or clotting disorders in her personal or family history.

Similarly to case 1 (Q24, N = 70 responses), the majority of respondents suggested that initial investigations should include blood test (94.3%), emergency MRI of the brain including an MRI angiography (92.9%), lumbar puncture and CSF analysis (88.6%), and brain CT scan including CT angiography (31.4%). Of the participants who considered blood tests essential (Q25, N = 70 responses), 98.6% would request full blood count including complete white cell count; 97.1% clotting tests including PTT, INR, fibrinogen and D dimers, and 90.0% would order immunology tests including ANA, ENA, complement factors, cardiolipin antibodies and ANCA; 42.9% suggested blood tests for adenosine deaminase 2 activity (ADA2) and 41.4% for interferon gamma release assay (IGRA) to exclude tuberculosis (Table 5).

When asked about blood immunology (Q26, N = 70 responses), 94.3% considered anti-phospholipid antibodies as required, followed by antinuclear antibodies, ANCA, anti-dsDNA antibodies, complement factors and activation of the

---

**Table 3 | Most likely diagnoses in case 1.**

| 5 most likely differential diagnoses (Q12) |
|------------------------------------------|
| 1. Selected progressive p-cPACNS          |
| 2. Transient p-cPACNS                     |
| 3. Ischaemic stroke                       |
| 4. Congenital anatomical deformity        |
| 5. Infections                             |
| 6. Arteriovenous (AV) malformation        |
| 7. CNS tuberculosis                       |
| 8. Migraine                               |
| 9. Tumor                                  |
| 10. Multiple sclerosis                     |
| 11. Traumatic intracranial bleeding       |

| Indicators of likely progressive p-cPACNS (Q13) |
|-----------------------------------------------|
| 1. Imaging results, namely involvement of more than one vessel, involvement of distal segments, and posterior vessel affected |
| 2. Clinical course with disease progression over 3 months or more |
| 3. Laboratory findings suggesting systemic inflammation |
| 4. Acute presentation with "systemic signs" |
| 5. Response to immune modulation |

---

**Table 4**
### TABLE 4 | Treatment decisions in case 1.

#### Induction of remission (Q14)

| Decision                                      | Count | Percentage |
|------------------------------------------------|-------|------------|
| 1 Intravenous Methylprednisolone (IVMP) over 5 days, followed by oral prednisolone | 68/73 | 93.2%      |
| 2 Intravenous Cyclophosphamide every month for 4-6 months | 47/73 | 64.3%      |
| 3 Mycophenolate mofetil (MMF) | 9/73 | 12.3%      |
| 4 Oral prednisolone | 3/73 | 4.1%       |

#### Prophylaxis of thromboembolic events (Q15)

| Decision                                      | Count | Percentage |
|------------------------------------------------|-------|------------|
| 1 IV heparin initially | 46/70 | 65.7%      |
| 2 Acetyl salicylic acid (ASA) | 19/70 | 27.1%      |
| 3 Combination of ASA and clopidogrel | 5/70 | 7.1%       |
| 4 “Others”: including low molecular weight heparin, Heparin 100 IU/Kg/12hr, Warfarin, clopidogrel alone or direct oral anticoagulants (DOAC); | 13/70 | 18.6%      |
| - | 0 | 0 | |

#### Post-acute phase thrombosis prophylaxis (Q16)

| Decision                                      | Count | Percentage |
|------------------------------------------------|-------|------------|
| 1 ASA | 33/70 | 47.1%      |
| 2 Subcutaneous heparin | 16/70 | 22.9%      |
| 3 Combination of ASA and clopidogrel | 10/70 | 14.3%      |
| 4 Warfarin | 8/70 | 11.4%      |
| 5 Clopidogrel | 4/70 | 5.7%       |
| 6 DOACs | 2/70 | 2.9%       |
| 7 None | 1/70 | 1.4%       |

#### Duration of thrombosis prophylaxis (Q17)

| Duration | Count | Percentage |
|----------|-------|------------|
| 3 months | 7/70 | 10%        |
| 6 months | 9/70 | 12.9%      |
| 12 months | 13/70 | 18.6%      |
| 18 months | 3/70 | 4.3%       |
| 24 months | 13/70 | 18.6%      |
| 36 months | 9/70 | 12.9%      |
| None | 1/70 | 1.4%       |

#### Immune modulating maintenance treatment (Q18)

| Decision                                      | Count | Percentage |
|------------------------------------------------|-------|------------|
| 1 MMF | 53/73 | 72.6%      |
| 2 Azathioprine | 15/73 | 20.5%      |
| 3 Oral prednisolone | 13/73 | 17.8%      |
| 4 Oral cyclophosphamide (following Fauci scheme) | 1/73 | 1.4%       |
| 4 TNF inhibitors | 1/73 | 1.4%       |

#### Duration of immune modulating treatment (Q19)

| Duration | Count | Percentage |
|----------|-------|------------|
| 3 months | 3/73 | 4.1%       |
| 6 months | 4/73 | 5.5%       |
| 12 months | 12/73 | 16.4%      |
| 18 months | 14/73 | 19.2%      |
| 24 months | 27/73 | 37.0%      |
| 36 months | 4/73 | 5.5%       |

#### Duration of oral corticosteroid treatment, including slow taper (Q20)

| Duration | Count | Percentage |
|----------|-------|------------|
| 3 months | 15/72 | 20.8%      |
| 6 months | 30/72 | 41.7%      |
| 12 months | 11/72 | 15.3%      |
| 18 months | 3/72 | 4.2%       |
| 24 months | 4/72 | 5.6%       |
| 36 months | 1/72 | 1.4%       |
| None | 1/72 | 1.4%       |

Of the 70 participants requesting a lumbar puncture (Q27, N = 70 responses), 98.6% considered cell counts and differentiation, followed by protein (95.7%), glucose (92.9%), microbial cultures (90.0%), opening pressure (84.3%), oligoclonal bands (81.4%), lactate (78.5%), and anti-NMDA and aquaporin antibodies.
TABLE 5 | Diagnostic approach in case 2.

| Diagnostic approach (Q24) |   |   |
|--------------------------|---|---|
| Blood tests including full blood counts, inflammatory markers and clotting tests | 66/70 | 94.3% |
| Emergency MRI of the brain including an MRI angiography | 65/70 | 92.9% |
| LUMBAR puncture to analyze the CSF | 62/70 | 88.6% |
| Brain CT scan including CT angiography | 22/70 | 31.4% |

Blood tests deemed essential (Q25)

|   |   |
|---|---|
| Complete blood cell count, including differential blood count | 69/70 | 98.6% |
| Clotting tests including PTT, INR, fibrinogen and D dimers | 68/70 | 97.1% |
| Immunology tests including ANA, ENA, complement factors, cardiolipin antibodies and ANCA | 63/70 | 90.0% |
| Adenosine deaminase (ADA) 2 activity | 30/70 | 42.9% |
| Interferon gamma release assay (IGRA) to exclude tuberculosis | 29/70 | 41.4% |

Blood immunology tests (Q26)

|   |   |
|---|---|
| Anti-phospholipid antibody testing | 66/70 | 94.3% |
| Antinuclear antibodies | 63/70 | 90.0% |
| Anti-neutrophil cytoplasmic antibodies (ANCA) | 64/70 | 91.4% |
| Anti-dsDNA antibodies | 57/70 | 81.4% |
| Complement factors and activation of the complement cascade | 53/70 | 75.7% |
| Anti-NMDA (N-methyl-D-aspartate) receptor and aquaporin antibodies | 38/70 | 54.3% |

Lumbar puncture (Q27)

|   |   |
|---|---|
| Cell counts, differentiation and protein quantification | 69/70 | 98.6% |
| Protein | 67/70 | 95.7% |
| Glucose | 65/70 | 92.9% |
| Microbial cultures | 63/70 | 90.0% |
| Opening pressure | 59/70 | 84.3% |
| Oligoclonal bands | 57/70 | 81.4% |
| Lactate | 55/70 | 78.5% |
| Anti-NMDA and aquaporin antibodies | 38/70 | 54.3% |

MRI techniques (Q28)

|   |   |
|---|---|
| MRI angiography | 60/68 | 88.2% |
| Fluid-attenuated inversion recovery (FLAIR) | 50/68 | 73.5% |
| Diffusion-weighted MRI sequences | 50/68 | 73.5% |
| T1 with fat saturation (FS) | 37/68 | 54.4% |
| T2FS | 34/68 | 50.0% |
| T1FS with contrast medium | 28/68 | 41.2% |
| TIRM/STIR | 27/68 | 39.7% |

(54.3%). Of 68 participants who considered emergency MRI (Q28, N = 68 responses), 88.2% requested MRI angiography, followed by FLAIR (73.5%), diffusion-weighted sequences (73.5%), T1FS with contrast medium (54.4%), T2FS (50.0%), T1 with FS (41.2%), and TIRM/STIR (39.7%) (Table 5).

Next, the participants were informed that autoantibodies in CSF and blood come back negative, there’s no evidence for clotting disorders or infection (including negative for TB and VZV PCR in CSF, serum VZV IgG positive, IgM borderline positive). Blood and CSF inflammatory markers remain within normal limits. DWI sequences unveiled altered diffusion capacity in the left hemisphere; Time of flight MR Angiography (TOF-MRA-)sequences demonstrate narrow caliber of left distal internal carotid artery and proximal anterior and medial cerebral artery. Post-gadolinium MRI sequences reveal contrast enhancement of the thickened vascular wall in the affected segments. Conventional angiography showed incomplete occlusion of the left A. cerebri media (Supplementary Material 1).

Respondents were then asked to choose the 5 most important differential diagnoses to consider (Q29, N = 70 responses). Most respondents (81.4%) considered p-cPACNS, likely transient related to VZV, followed by ischaemic stroke (70.0%), transient p-cPACNS not related to VZV (61.4%) and infections e.g., meningitis (32.9%) (Table 6).

When asked which medication to administer for induction treatment (Q30, N = 69 responses), 53/69 (76.8%) respondents suggested IVMP over 5 days, followed by 18/69 who considered intravenous Cyclophosphamide every month for 4–6 months (26.1%), 12/69 MMF (17.4%), 9/69 (13.0%) oral Prednisolone, and 2/69 Azathioprine (2.9%). None of the participants chose oral Cyclophosphamide for induction treatment. Respondents
were asked how long to continue oral corticosteroid treatment including slow taper for (Q34, N = 66 responses), they answered: 3 months (25/66, 37.9%), 6 months (23/66, 34.9%), 12 months (7/66, 10.6%), 18 months (0/66, 0.0%), 24 months (2/66, 3.0%) and 36 months (1/66, 1.5%). Five of 66 respondents answered no to prescribing oral corticosteroid treatment (7.6%).

Considering prophylaxis of thromboembolic events (Q31, N = 67 responses), most respondents agreed on administering IV Heparin initially as anticoagulation treatment (52.2%) in the acute phase, followed by ASA (29.9%), a combination of ASA and clopidogrel (6.0%) and warfarin (4.5%). Considering post-acute phase prophylaxis (Q32, N = 66 responses), a majority of respondents would prescribe Aspirin (53.0%), followed by subcutaneous Heparin (18.2%), a combination of Aspirin and Clopidogrel (9.1%), warfarin (7.6%), clopidogrel or DOACs (4.6% each). Regarding discontinuation of anticoagulation treatments (Q35, N = 63 responses), respondents answered after 3 months (11.1%), 6 months (17.5%), 12 months (20.6%), 18 months (3.2%), 24 months (12.7%) and 35 months (6.4%). Five of 63 respondents answered they would not administer anticoagulation treatment (7.9%) (Table 7).

Monitoring of disease activity and damage using MRI (Q36, N = 69 responses) was suggested after 3 months by 60/69 (87.0%) respondents, after 6 months by 32/69 (46.4%) and after 12 months by 25/69 (36.2%). Eight of 69 respondents would repeat MRI after 18 months (11.6%), 17/69 after 24 months (24.6%) and 6/69 after 36 months (8.7%). Clinical follow up (Q37, N = 70 responses) was considered reasonable at 3 months by 58/70 respondents (82.9%), at 6 months by 24/70 (34.3%), 12 months by 24/70 (34.3%), 18 months by 16/70 (22.9%), 24 months by 18/70 (25.7%), and after 36 months by 14/70 (20.0%).

To assess how participants would alter their approach based on evidence of VZV infections temporally associated with p-cPACNS, they were provided with alternative test results: After evidence of VZV infections temporally associated with p-cPACNS, 57/70 (81.4%) of responders indicated initially treating with IVMP over 5 days followed by oral Prednisolone.

As a result of positive testing for VZV (Q38, N = 68 responses), the majority of the respondents indicated they would treat the patients with IV Acyclovir treatment over 14 days (58/68, 85.3%), 32/68 (47.1%) of responders indicated initially treating with IVMP over 5 days followed by oral Prednisolone. Less common answers indicated by participants were induction with oral Prednisolone, followed by oral Prednisolone taper (10/68, 14.7%), IV Cyclophosphamide (2/68, 2.9%), MMF induction treatment (2/68, 2.9%), Azathioprine (1/68, 1.5%). None of the participants indicated they would treat the patient with oral Cyclophosphamide (Fauci scheme).

**Medical Specialties Involved**

For both cases, participants were asked to indicate which specialties should be involved in the patient’s care (Figure 3A, Q23, N = 72 responses and Figure 3B, Q39, N = 69 responses). Answers suggested multi-professional approaches in both clinical scenarios.

**Influence of Experience in Approach to Diagnosis and Treatment**

Finally, we aimed to assess whether professional experience of the responders (years of practice, number of PACNS patients treated) associated with variable approaches to diagnosis and treatment (Q4, N = 91 responses). As responses varied significantly, especially among answers not within the top 3, only the top three most commonly selected answers for diagnosis and treatment methods were used. Responses related to case 1 were associated with years of experience (Supplementary Table 1, Figures 4A–D) and p-cPACNS patients treated (Supplementary Table 2, Figures 5A–D). In case 1, overall years of experience correlated with making the “correct diagnosis” likely progressive p-cPACNS (Figure 4A). Surprisingly, the number of patients treated (Figure 5A)

---

**TABLE 6 | Most likely diagnoses in case 2.**

| Rank | Diagnosis                                      | Frequency | Percentage |
|------|-----------------------------------------------|-----------|------------|
| 1    | p-cPACNS, likely transient related to VZV      | 57/70     | 81.4%      |
| 2    | Ischaemic stroke                              | 49/70     | 70.0%      |
| 3    | Transient p-cPACNS not related to VZV          | 44/70     | 62.9%      |
| 4    | CNS tuberculosis                              | 43/70     | 61.4%      |
| 5    | Infections e.g., meningitis                   | 23/70     | 32.9%      |

**TABLE 7 | Anticoagulation in case 2.**

| Rank | Prophylaxis of thromboembolic events (Q31) | Frequency | Percentage |
|------|--------------------------------------------|-----------|------------|
| 1    | IV heparin initially                        | 35/67     | 52.2%      |
| 2    | Acetyl salicylic acid (ASA)                 | 20/67     | 29.9%      |
| 3    | Combination of ASA and clopidogrel          | 4/67      | 6.0%       |
| 4    | Warfarin                                    | 3/67      | 4.5%       |
|      | Clopidogrel alone or direct oral anticoagulants (DOAC) | 0 | 0 |

| Rank | Post-acute phase thrombosis prophylaxis (Q32) | Frequency | Percentage |
|------|------------------------------------------------|-----------|------------|
| 1    | ASA                                           | 35/66     | 53.0%      |
| 2    | Subcutaneous heparin                          | 12/66     | 18.2%      |
| 3    | None                                          | 8/66      | 12.1%      |
| 4    | Combination of ASA and clopidogrel            | 6/66      | 9.1%       |
| 5    | Warfarin                                      | 5/66      | 7.6%       |
| 6    | Clopidogrel                                    | 3/66      | 4.6%       |
| 7    | DOACs                                         | 3/66      | 4.6%       |

| Rank | Duration of thrombosis prophylaxis (Q35) | Frequency | Percentage |
|------|------------------------------------------|-----------|------------|
| 1    | 3 months                                  | 7/63      | 11.1%      |
| 2    | 6 months                                  | 11/63     | 17.5%      |
| 3    | 12 months                                 | 13/63     | 20.6%      |
| 4    | 18 months                                 | 2/63      | 12.7%      |
| 5    | 24 months                                 | 8/63      | 18.6%      |
| 6    | 36 months                                 | 4/63      | 6.4%       |
| 7    | None                                      | 5/63      | 7.9%       |
did not correlate with making the “correct diagnosis” to the same extent. A similar trend was seen when considering the use of cyclophosphamide. Colleagues with more years of experience in their specialty less frequently considered cyclophosphamide, but more commonly MMF as induction treatment (Figure 4B), which also did not correlate as well with the number of cPACNS patients treated (Figure 5B). Response related to case 2 were also associated with years of experience (Supplementary Table 3, Figures 6A–C) and p-cPACNS patients treated (Supplementary Table 4, Figures 7A–C).

DISCUSSION

Childhood PACNS is a rare disease (13) that can cause significant damage, result in the death of individuals affected, or affect quality of life, psychomotor development, and lastly cause significant cost to healthcare systems (4). Diagnostic and therapeutic delay is common and caused by multiple factors, including a large number of differential diagnoses, overall lack of awareness, and the absence of standardized protocols for children with neurological deficits in many institutions. Furthermore, the absence of widely accepted, prospectively and independently evaluated diagnostic criteria and treatment algorithms, complicate the situation (14).

Especially in rare conditions it can be challenging to develop evidence-based and widely accepted diagnostic or classification criteria. The paucity of evidence for treatment is in part due to small patient numbers and therefore reduced interest by industry and funding bodies, and the fact that “standard-of-care” approaches are considered effective and the introduction of “placebo controls” would be unethical. Currently, diagnostic approaches and classification of cPACNS relies on suggested, but not prospectively evaluated criteria, and treatment is based on mostly retrospective and relatively small case series and/or expert opinion (10). In such situations, establishing consensus on diagnostic and treatment plans to harmonize approaches and prospectively collect meaningful clinical datasets in relation to consensus treatment plans can be a helpful tool to generate evidence and allow improvement of outcomes in patients with rare diseases (11, 15–17).

The establishment of consensus treatment plans follows a structured approach, including surveying the current standard of care among experts as an early step (15–17). Here, we present results from an internationally shared online survey collecting information on diagnostic and therapeutic approaches of clinicians experienced with cPACNS.

Overall response rates were relatively low (ca. 1%), which may have been caused by limited experience with the condition across medical specialties and countries. Indeed, only 19.6% of responders had <5 years’ clinical experience as a specialist suggesting that mostly more senior colleagues with personal experience in diagnosing and treating PACNS
patients responded. Only 74.7% of participants had personal experience in the care of patients with cPACNS. This survey represents opinions from a relatively small number of pediatric rheumatologists, neurologists and other experts involved in the management of this rare condition. It will remain to be determined, e.g., through Delphi questionnaires and subsequent expert consensus meetings, whether responses are indeed widely representative for standard-of-care.

Diagnostic approaches for both forms of cPACNS queried here (progressive vs. transient p-cPACNS) did not vary between forms. Overall, 75.3% agreed that MRI is essential for diagnosing p-cPACNS, 26.8% favor lumbar puncture and CSF analyses, 20.2% would perform CT scans as an alternative to MRI. Interestingly, when confronted with the two case scenarios, responses were slightly different. MRI and blood laboratory tests were considered the most important and therefore likely most helpful tools with agreement between 90.5 and 94.3%, followed by CSF analyses (82.4 vs. 88.6%), and CT scans (23.0 vs. 31.4%).

Agreement regarding appropriate MRI strategies between respondents and cases was strong. Most participants would request MRI angiography (87.3 vs. 88.2%), followed by FLAIR (77.5 vs. 73.5%), diffusion weighted imaging (74.7 vs. 73.5%), T1 FS with contrast application (53.5 vs. 54.4), T2 FS (52.1 vs. 50.0%), T1 FS (42.3 vs. 41.2%), and lastly TIRM or STIR (39.4 vs. 39.7%). Based on published reports, MRI angiography is a strong tool to assess local perfusion and (to some extent) vessel obstruction (18), FLAIR sequences suppress cerebrospinal fluid (CSF) effects which is effective in identifying periventricular hyperintense lesions, such as multiple sclerosis plaques (19). Diffusion weighted imaging helps differentiating between new and old lesions and assess local perfusion in relation to vessel anomalies (20). As T1 sequences can be a strong tool to quantify vessel wall oedema and contrast enhancement can be a surrogate marker of active inflammation (21), it appears surprising that not more colleagues chose these examinations. However, radiologists were under-represented in this survey, but are certainly key members of multidisciplinary teams diagnosing and monitoring patients with cPACNS.

While patients with transient pPACNS can exhibit mild clinical symptoms indicative of focal neurological deficits, patients with progressive pPACNS usually present with symptoms of both focal and diffuse neurological deficits, including cognitive impairment, headaches and in some cases seizures (10, 22, 23). As 80.8% of participants agreed with the aforementioned approach to stratify patients by likely risk for disease progression and classified case 2 as transient p-cPACNS (81.4%), it appears surprising that 69.9% also stated that case 1 with posterior arteries affected may have transient disease.
Based on participants’ responses, most important blood tests include blood cell counts and differentiation (99% both), immunology profiling (90–95%, including APL, ANA, ANCA, dsDNA, complement function, NMDA/aquaporin antibodies). Additional tests frequently requested included ADA2 levels for the exclusion of DADA2, and IGRA to exclude TBC, as both conditions have been reported to cause neuroinflammation/vasculitis (24, 25). Lumbar puncture/CSF analysis was suggested to include CSF opening pressure (85.6 vs. 84.3%), cell counts and protein (98.6 vs. 98.6%), microbiological cultures (93.2 vs. 90.0%), glucose levels (90.5 vs. 92.9%), oligoclonal bands (89.1 vs. 81.4%), lactate (74.3 vs. 78.5%), and NMDA/aquaporin antibodies (68.9 vs. 54.3%). Interestingly, as not included in the multiple-choice options and potentially helpful when considering infectious and/or reactive causes of vasculitis, none of the participants suggested virus serologies or PCRs in blood or CSF. However, virus diagnostics had been included in the previous question, which may have confused the participants.

Therapeutic approaches varied between participants and (not surprisingly) progressive vs. transient disease. In progressive p-cPACNS (case 1), most participants would have chosen an induction treatment regimen with IVMP (93.2%), followed by CPM (64.3%), MMF (12.3%) and oral prednisolone (4.1%), while in transient p-cPACNS (case 2), CPM was less frequently chosen (26.1%), while oral prednisolone appears to play a bigger role (13.0%). Provided potential side-effects and the transient nature of the disease, the use of CPM in transient p-cPACNS appears surprising, but prospective trials are lacking (3). Notably, evidence for a recent infection with VZV in transient p-cPACNS would significantly reduce the likelihood to prescribe CPM (2.9%) or MMF (2.9%). A majority of colleagues would include antiviral acyclovir in the treatment regimen (85.3%), and use of methylprednisolone was only considered by 47.1% (as compared to 76.8% without evidence of VZV). This appears somewhat surprising as vasculitis in VZV is likely of reactive nature and not caused by the virus itself (26), and patients may benefit from immune modulation. However, clinical evidence through trials does not exist. While overall agreement between less and more experienced colleagues was strong, years of experience associated with diagnostic certainty in case 1 (progressive p-cPACNS) and caution with the use of CPM, favoring MMF for induction treatment. This correlation was not seen when considering the number of PACNS patients treated. Indeed, more recently preliminary reports suggest that CPM may be replaced by alternatives, such as MMF in p-cPACNS (4) and other (systemic) autoimmune/inflammatory conditions, such as SLE (27). However, this may not apply to all individuals and has to be followed in prospective case collections/registers and clinical trials.

As maintenance treatment may only/mostly be necessary in cases with prolonged disease activity, it was only queried...
for progressive p-cPACNS. A majority of participants favor MMF (72.2%), followed by azathioprine (21%), prednisolone (18%), CPM (i.v., 14%, oral 1%), rituximab (10%), methotrexate (5%) and TNF inhibitors (1%). Responses reflect few available published reports in which aforementioned regimens had been chosen. However, data is limited to relatively small and retrospective case collections, and evidence from prospective trials is lacking.

Duration of corticosteroid treatment was recorded in progressive and transient p-cPACNS, and was largely comparable. Most colleagues would treat patients with transient disease for 3 (37.9%) or 6 months (34.9%), while slightly more would treat for 6 (41.7%) than 3 (20.8%) months in progressive p-cPACNS.

Antithrombotic prophylaxis was considered essential by a majority of participants in the acute and post-acute phase in both progressive and transient p-cPACNS. Heparin i.v., in the
acute phase was deemed important in progressive (65.7%) and transient (52.2%) disease, followed by aspirin (27.1 vs. 29.9%), and the combination of aspirin and clopidogrel (7.1 vs. 6.0%). For post-acute phase prophylaxis, colleagues consider aspirin (47.1 vs. 53.0%), heparin s.c. (22.9 vs. 18.2%), aspirin and clopidogrel in combination (14.3 vs. 7.6%), clopidogrel (6 vs. 4.6%), DOACs (vs. 4.6% each). As many as 12.1% of colleagues would not prescribe post-acute phase thromboembolism prophylaxis in patients with transient p-cPACNS. Suggested duration of anticoagulant treatment did not vary dramatically, most colleagues suggested 12 months (18.6% in progressive and 20.6% in transient p-cPACNS), followed by 24 months (18.6 vs. 12.7%). Interestingly, few colleagues preferred 18 months treatment (4.3 vs. 3.2%). However, this reflects the absence of evidence and the urgent need for data collection and generation of consensus.

Proposed monitoring of disease activity and damage was comparable between both progressive and transient p-cPACNS, and, based on participants’ responses, should include MRI imaging and clinical examinations every 3 months. However, agreement significantly reduced over time, and at 18 months only 15 vs. 12% found MRI and 26 vs. 23% clinical examinations to be of importance. This is special interest, as a majority of 73% would continue immune modulating treatment for up to 24 months, and flares appear more likely with or after treatment discontinuation.

Consensus on a multi-professional approach to diagnosis and treatment was strong for both transient and progressive p-cPACNS.

CONCLUSION

In the absence of widely accepted and prospectively evaluated diagnostic criteria and evidence-based therapeutic strategies for p-cPACNS, clinical management varies between centers. Diagnostic and therapeutic strategies vary considerably, especially in regards to therapeutics used and treatment duration. Based on data from this survey, Delphi questionnaires will be developed to define statements to be used toward expert consensus meetings. This process will aim at the development of diagnostic and treatment plans for patients with p-cPACNS following agreed consensus-based protocols.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

All authors were involved in study planning and manuscript preparation, AQ and CH lead on data analysis and preparation of the first written draft, all authors read and agreed on the final version of this manuscript.

ACKNOWLEDGMENTS

The authors thank Jana Hörstermann, Deutsches Rheuma-Forschungszentrum, Berlin, Germany for support in preparing and executing the Survey.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2021.654537/full#supplementary-material

REFERENCES

1. Benseler SM, Silverman E, Aviv RI, Schneider R, Armstrong D, Tyrrell PN, et al. Primary central nervous system vasculitis in children. Arthritis Rheum. (2006) 54:1291–7. doi: 10.1002/art.21766
2. Börnbaum J, Hellmann DB. Primary angiitis of the central nervous system. Arch Neurol. (2009) 66:704–9. doi: 10.1001/archneurol.2009.76
3. Smitka M, Bruck N, Engellandt K, Hahn G, Knoefer R, von der Hagen M. Clinical perspective on primary angiitis of the central nervous system in childhood (cPACNS). Front Pediatr. (2020) 8:281. doi: 10.3389/fped.2020.00281
4. Walsh S, Knoefler R, Hahn G, Lohse J, Berner R, Brenner S, et al. Childhood primary large vessel CNS vasculitis: single-centre experience and review of the literature. Clin Exp Rheumatol. (2017) 35(Suppl. 103):213–20.
5. Byram K, Haj-Ali RA, Calabrese L. CNS vasculitis: an approach to differential diagnosis and management. Curr Rheumatol Rep. (2018) 20:37. doi: 10.1007/s11944-018-0747-z
6. Haj-Ali RA, Singhal AR, Benseler S, Molloy E, Calabrese LH. Primary angiitis of the CNS. Lancet Neurol. (2011) 10:561–72. doi: 10.1016/S1474-4422(11)70081-3
7. Benseler SM. Central nervous system vasculitis in children. Curr Rheumatol Rep. (2006) 8:442–9. doi: 10.1007/s11926-006-0040-4
8. Calabrese LH, Malley JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine. (1988) 67:20–39. doi: 10.1097/00005672-198801000-00002
9. Calabrese LH, Furlan AI, Gragg LA, Ropos TJ. Primary angiitis of the central nervous system: diagnostic criteria and clinical approach. Cleve Clin J Med. (1992) 59:293–306. doi: 10.3949/ccjm.59.3.293
10. Beelen J, Benseler SM, Dropol A, Ghali B, Twilt M. Strategies for treatment of childhood primary angiitis of the central nervous system. Neurol Neuroimmunol Neuroinflamm. (2019) 6:e567. doi: 10.1212/NXI.0000000000000567
11. Hinze CH, Holzinger D, Lainka E, Haas JP, Speth F, Kallinich T, et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J. (2018) 16:7. doi: 10.1186/s12996-018-0224-2
12. Wilkinson NM, Page J, Uribe AG, Espinosa V, Cabral DA. Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a childhood arthritis and rheumatology alliance (CARRA) survey. J Rheumatol. (2007) 34:224–6.
13. Twilt M, Benseler SM. The spectrum of CNS vasculitis in children and adults. Nat Rev Rheumatol. (2011) 8:97–107. doi: 10.1038/nrrheum.2011.197
14. Beuker C, Schmidt A, Strunk D, Sporns PB, Wiendl H, Meuth SG, et al. Primary angiitis of the central nervous system: diagnosis and treatment. Ther Adv Neurol Disord. (2018) 11:1756286418785071. doi: 10.1177/1756286418785071
15. de Graeff N, Groot N, Brogan P, Ozen S, Avcin T, Bader-Meunier B, et al. European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides - the SHARE initiative. Rheumatology. (2019) 58:656–71. doi: 10.1093/rheumatology/key322
16. Kuemmerle-Deschner JB, Hansmann S, Wulffraat NM, Vastert SJ, Hens K, Anton J, et al. Recommendations for collaborative paediatric research including biobanking in Europe: a single hub and access point for paediatric rheumatology in Europe (SHARE) initiative. *Ann Rheum Dis*. (2018) 77:319–27. doi: 10.1136/annrheumdis-2017-211904

17. Li SC, Fuhlbrigge RC, Laxer RM, Pope E, Ibarra MF, Stewart K, et al. Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study. *Pediatr Rheumatol Online J*. (2019) 17:43. doi: 10.1186/s12969-019-0350-5

18. Broncano J, Vargas D, Bhalla S, Cummings KW, Raptis CA, Luna A, CT and MR imaging of cardiothoracic vasculitis. *Radiographics*. (2018) 38:997–1021. doi: 10.1148/rg.2018170136

19. Klawiter EC. Current and new directions in MRI in multiple sclerosis. *Continuum*. (2013) 19:1058–73. doi: 10.1212/01.CON.0000433283.00221.37

20. Lee SH, Nah HW, Kim BJ, Ahn SH, Kim JS, Kang DW, et al. Role of perfusion-weighted imaging in a diffusion-weighted-imaging-negative transient ischemic attack. *J Clin Neurol*. (2017) 13:129–37. doi: 10.3988/jcn.2017.13.2.129

21. Ammirati E, Moroni F, Pedrotti P, Scotti I, Magnoni M, Bozzolo EP, et al. Non-invasive imaging of vascular inflammation. *Front Immunol*. (2014) 5:399. doi: 10.3389/fimmu.2014.00399

22. Aviv RI, Benseler SM, Silverman ED, Tyrrell PN, Deveber G, Tsang LM, et al. MR imaging and angiography of primary CNS vasculitis of childhood. *AJNR Am J Neuroradiol*. (2006) 27:192–9.

23. Sébire G, Fullerton H, Riou E, deVeber G. Toward the definition of cerebral arteriopathies of childhood. *Carr Opin Pediatr*. (2004) 16:617–22. doi: 10.1097/01.mop.0000144441.29899.20

24. Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. *J Clin Immunol*. (2018) 38:569–78. doi: 10.1007/s10875-018-0525-8

25. Jain A, Misra DP, Ramesh A, Basu D, Jain VK, Negi VS. Tuberculosis mimicking primary systemic vasculitis not to be missed! *Trop Doct*. (2017) 47:158–64. doi: 10.1177/0049475516687432

26. Kennedy PGE, Gershon AA. Clinical features of varicella-zoster virus infection. *Viruses*. (2018) 10:609. doi: 10.3390/v10110609

27. Massias JS, Smith EMD, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. *Lupus*. (2020) 29:474–81. doi: 10.1177/0961203320909156

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2021 Quan, Brunner, Rose, Smitka, Hahn, Pain, Häfner, Speth, Gerstl and Hedrich. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*